Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Not Applicable
Recruiting
- Conditions
- Diabetes Mellitus, Type 2Type 2 DiabetesDiabetesType 2 Diabetes MellitusType2diabetes
- Interventions
- Device: ReCET TreatmentDevice: Sham Procedure
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Endogenex, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT06267391
- Locations
- ๐บ๐ธ
University of Alabama, Birmingham, Alabama, United States
๐บ๐ธCentral Alabama Research, Birmingham, Alabama, United States
๐บ๐ธVelocity Clinical Research, Gardena, Gardena, California, United States
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
Not Applicable
Active, not recruiting
- Conditions
- DiabetesMetabolic DiseaseEndocrine System DiseasesDiabetes Type 2Diabetes Mellitus, Type 2Diabetes MellitusGlucose Metabolism Disorders
- Interventions
- Device: The Endogenex Device
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Endogenex, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05014204
- Locations
- ๐บ๐ธ
Cuyuna Regional Medical Center, Crosby, Minnesota, United States
๐บ๐ธUniversity of Southern California, Los Angeles, California, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes
Not Applicable
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Device: The DyaMX Device
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Endogenex, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04725890
- Locations
- ๐ฆ๐บ
The BMI Clinic, Sydney, New South Wales, Australia
๐ฆ๐บSt Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
ยฉ Copyright 2025. All Rights Reserved by MedPath